Synergy Innovation

시너지이노베이션 · 048870

Health Care Medical Devices · KOSDAQ

Small-cap

Market cap US$109.8M (₩151.5B)

Overview

Synergy Innovation makes microbial culture media, the nutrient-rich substances used to grow and detect bacteria in laboratory and pharmaceutical-manufacturing settings.

It supplies these products, along with related in-vitro diagnostic reagents, to hospitals, testing centres, and pharmaceutical companies across South Korea. Listed on KOSDAQ, Korea's tech and small-cap exchange, the company operates across three business divisions, biotechnology, medical, and health functional foods, with the medical division generating the majority of its revenue.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$81.9M

▲ +24.8% YoY

Operating profit · FY2025

US$13.9M

▲ +19.0% YoY

Net income · FY2025

US$8.1M

▼ −38.4% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$60.3M(₩83.2B)	US$65.7M(₩90.6B)	US$81.9M(₩113.1B)
Operating profit	US$10.9M(₩15B)	US$11.7M(₩16.1B)	US$13.9M(₩19.2B)
Net income	US$5.5M(₩7.5B)	US$13.1M(₩18.1B)	US$8.1M(₩11.2B)

Revenue

FY2023US$60.3M
FY2024US$65.7M
FY2025US$81.9M

Operating profit

FY2023US$10.9M
FY2024US$11.7M
FY2025US$13.9M

Net income

FY2023US$5.5M
FY2024US$13.1M
FY2025US$8.1M

Key ratios (FY2025)

ROE

4.1%

Debt/Eq

23.7%

Op. margin

16.9%

Net margin

9.9%

Rev. YoY

▲ +24.8%

Why it matters

The consolidated group comprises seven entities in total, including a drug-discovery subsidiary, Neurobiozen, that focuses on new-medicine research and development.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?